FDA Approves Iloperidone for Acute Treatment of Manic, Mixed Episodes in Bipolar I
Drug Topics
APRIL 4, 2024
The drug was previously approved in 2009 to treat schizophrenia.
Thu.Apr 04, 2024
387 
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
PharmaVoice
APRIL 4, 2024
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Federal Retail Pharmacy Program Partners Critical in Ensuring Vaccine Access
Drug Topics
APRIL 4, 2024
Understanding the role of pharmacies in vaccination rates can help prepare officials for the next public health emergency.
Baylor wins 2024 STAT Madness with ‘smoke alarm’ for viral disease outbreaks
STAT
APRIL 4, 2024
It began with injecting monkeys with sewage to see if they developed polio. Building off that early polio work from the 1940s, researchers from the Baylor College of Medicine analyzed public wastewater and showed they could detect over 450 disease-causing viruses. Their study demonstrating the power of sewage as an early-warning system for outbreaks won the 2024 STAT Madness popular vote.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Approves Antibiotic Ceftobiprole Medocaril for Injection for 3 Indications
Drug Topics
APRIL 4, 2024
The antibiotic was approved to treat Staphylococcus aureas bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
STAT+: Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise
STAT
APRIL 4, 2024
On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug , Relyvrio, after a large clinical trial showed that the medicine, approved by the Food and Drug Administration in 2022, was not effective. Amylyx’s co-CEOs, Joshua Cohen and Justin Klee, had previously publicly promised that they would withdraw the drug if further testing failed to show a benefit.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
STAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market
STAT
APRIL 4, 2024
WASHINGTON — Boehringer Ingelheim is laying off or relocating its sales staff for its Humira biosimilar Cyltezo in a sign of how difficult it’s been to get drug middlemen to adopt less-expensive versions of the blockbuster, the company confirmed. Some employees may find positions elsewhere in the company, but they are mostly being pulled from the field.
Diagnostics company Binx Health banks $65M to drive growth of point-of-care testing
Fierce Healthcare
APRIL 4, 2024
Binx Health is a health technology company aiming to speed up the time between diagnosis and treatment of sexually transmitted infections with a point-of-care diagnostic solution. | Binx Health is a health technology company aiming to speed up the time between diagnosis and treatment of sexually transmitted infections with a point-of-care diagnostic soultion.
Opinion: Hospital care costs are out of control. Price caps can help
STAT
APRIL 4, 2024
Here’s just the tip of the iceberg: $722.50 for a nurse to push a drug into an IV. $21,500 for ten stitches. The prices charged by hospitals are exorbitant and rising. Private health insurance premiums paid by working age adults are rising rapidly. Many Americans skip necessary medical care, while those who do get treated can end up bankrupt.
Marshfield Clinic Health System laying off hundreds of furloughed employees
Fierce Healthcare
APRIL 4, 2024
Months after furloughing hundreds of its employees, Marshfield Clinic Health System has informed many of those workers that they will be terminated “in early May,” a spokesperson of the 11-hospital | Though more than five dozen of the employees furloughed in January have found new positions in the organization, hundreds of others will be eliminated "in early May.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
What ‘de-extinction’ of woolly mammoths can teach us: a Q&A with evolutionary biologist Beth Shapiro
STAT
APRIL 4, 2024
Humans have long tinkered with the evolutionary trajectories of other species. Thousands of years ago we tamed wolves into dogs and transformed a wild grass into the agricultural wonder wheat. Within the past few centuries, we exterminated the Tasmanian tiger and doomed the dodo bird to oblivion. Now, we stand on the brink of an ambitious new era in how humans may transfigure life around us: by pursuing the science of de-extinction, or the resurrection of species once lost to this world.
AI-powered real-world evidence generation for biotechs
pharmaphorum
APRIL 4, 2024
Discover how AI-powered real-world evidence generation is revolutionising the biotech industry, providing valuable insights for biopharma companies to make informed decisions. Learn more about the impact of RWD on biotechs.
STAT+: Nuclear Regulatory Commission advisers beset by conflicts of interest, report finds
STAT
APRIL 4, 2024
The oversight division of a U.S. government agency tasked with ensuring the safe use of radioactive materials issued a recent report that the agency’s advisers had key undisclosed conflicts of interest, raising fresh concerns about controversial decisions around the reporting of radioactive injection accidents. The report, released on March 26 and conducted by the Nuclear Regulatory Commission’s (NRC) Office of the Inspector General, identified conflicts of interest involving two m
Is 2024 the Year for Psychedelic Medicine?
Pharmacy Times
APRIL 4, 2024
MDMA-assisted therapy and psilocybin currently lead the way with potential approvals by the FDA.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Opinion: For national security, the U.S. must maintain its biotech dominance
STAT
APRIL 4, 2024
For more than a century, the United States has been the undisputed leader in medical and biotechnology innovation. It saved millions of lives by mass-producing the first polio vaccines. U.S. researchers discovered new antibiotics that turned once-fatal infections into minor ailments, and developed antiretroviral cocktails that transformed HIV from a death sentence into a manageable, chronic disease.
Biden slams asthma inhaler prices in White House address
pharmaphorum
APRIL 4, 2024
President Joe Biden has reiterated his pledge to take action against high drug prices and “beat big pharma,” singling out the cost of asthma inhalers in a speech delivered at a White House event with US Senator Bernie Sanders, a long-time critic of the industry’s pricing policies in the US.
Health tech investor Glen Tullman launches 62 Ventures, a new $100 million fund
STAT
APRIL 4, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. First the news: Glen Tullman, currently the CEO Transcarent , has a new, roughly $100 million venture fund, called 62 Ventures.
Trial finds benefit for GLP-1 agonist in Parkinson’s
pharmaphorum
APRIL 4, 2024
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug class.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
How resurrecting extinct species might impact medicine
STAT
APRIL 4, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hey, it’s Meghana. Today, we see how the GLP-1s might be harnessed for Parkinson’s, we learn about species de-extinction efforts, and BIO’s CEO tells us why the U.S. needs to stay on top in biotech.
Conference report: Reuters Pharma USA
pharmaphorum
APRIL 4, 2024
Last week, pharmaphorum editor-in-chief Jonah Comstock travelled to Philadelphia for Reuters Pharma USA. On today’s podcast, he chats with guest host and Deep Dive editor Eloise McLellan about his biggest takeaways from the two-day event.
Opinion: How climate change is driving a global epidemic of immune health problems, and how to stop it
STAT
APRIL 4, 2024
Many of the effects of climate change play out at a very large scale: Heatwaves that grip entire continents. Flooding that submerges vast swaths of island nations and continental coastal areas. Other effects are far less visible because they’re taking place inside people’s bodies. That doesn’t make them any less dangerous.
Praia emerges with $20m for digital health platform
pharmaphorum
APRIL 4, 2024
Healthcare system Providence has spun out a new company, Praia Health, focused on a platform to build and sustain connections between patients and health providers. The new company starts life with $20 million in Series A funding and a mission to develop the Praia Health Identity and Engagement Platform, which was launched within Providence’s digital innovation group (DIG) incubator in 2022 and already handles around 3.5 million user accounts.
Why very few people who are eligible for a cochlear implant actually get one
STAT
APRIL 4, 2024
Cochlear implants have successfully improved hearing loss for decades, but few people who qualify for an implant actually get it. Even in countries with universal healthcare, the adoption rates are dismal. Researchers are finding further disparities for marginalized communities, especially for Black and Asian patients, according to a recent study of British hospitals published Thursday in PLOS Medicine.
Think Outside the Box for Front-End Profit Opportunities in the Pharmacy
Pharmacy Times
APRIL 4, 2024
Taking steps to improve front-end sales takes some time and out-of-the-box thinking, but it can prove profitable and improve word-of-mouth recommendations.
STAT+: Weed for weight loss, and more from Biotech Land
STAT
APRIL 4, 2024
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Bankruptcies, restructurings, clinical trial setbacks, and falling stock prices: It’s been a disconcerting week in Biotech Land. Luckily, this newsletter has arrived like a warm hug.
A Call to Pharmacists in the Delivery of Oncology Care
Pharmacy Times
APRIL 4, 2024
The expanded role of oncology pharmacists includes the opportunity to work in ambulatory settings, infusion centers, delivery of specialized in pharmacy services, evaluation of investigational new drugs, and manager roles in drug chain supply and in coordination of care.
Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
Fierce Pharma
APRIL 4, 2024
Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. | Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. And 70% of the company's staff will soon lose their jobs.
FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment
Pharmacy Times
APRIL 4, 2024
Bimekizumab-bkzx (Bimzelx; Union Chimique Belge) is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin (IL)-17A and IL-17F.
Does exercise help with period cramps?
The Checkup by Singlecare
APRIL 4, 2024
Menstrual cramps are commonly described as a dull, throbbing, or spasming sensation in the lower abdomen or pelvic area. Also known as period cramps, they are caused by contractions of the uterus during menstruation and triggered by the release of prostaglandins, hormone-like substances that cause pain and inflammation. Low-intensity exercise, like walking, swimming, or yoga, can help alleviate painful periods by releasing endorphins, increasing blood flow, and reducing tension in the body.
Valerian: Root of All Zzz’s or Just Another Bedtime Story?
Pharmacy Times
APRIL 4, 2024
Several studies on valerian have been conducted in the past 50 years for indications varying from insomnia, anxiety, restless leg syndrome, headaches, and more.
STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more
STAT
APRIL 4, 2024
Top of the morning to you, and a fine one it is. After two days of downpours and strong winds, the Pharmalot campus is now enveloped by sunny skies and pleasant breezes, which is very much a welcome change. To celebrate, we are quaffing cups of stimulation. Our choice today is toasted coconut. As always, you are invited to join us. Meanwhile, we are proud to present our latest list of interesting items for you to peruse.
Pharma Pulse 4/4/24: Baltimore Bridge Collapse Upends US Supply Chains, Can Employees Realistically Expect Any Good Jobs for 2024? & more
Pharmaceutical Commerce
APRIL 4, 2024
The latest news for pharma industry insiders.
City of Hope discloses data breach impacting 827K patients' personal and health information
Fierce Healthcare
APRIL 4, 2024
City of Hope discloses data breach impacting 827K patients' personal and health information hlandi Thu, 04/04/2024 - 13:48
Let's personalize your content